This article is based on a poster originally authored by An Ouyang, Spencer Chiang and Chao Wang. Antibody-drug conjugates (ADCs) are a new class of anti-cancer therapeutics that are both novel and ...
One of the fastest-growing segments of pharmaceuticals, as highlighted at the 2024 J.P. Morgan Healthcare Conference, is the antibody-drug conjugate (ADC) segment. ADCs consist of four main elements: ...
This novel approach utilizes cysteine-engineered antibodies which allows for the development of uniform and homogenous ADCs with precise control of the drug to antibody ratio (DAR). The drug-payload, ...
The concept of an antibody drug conjugate, or ADC, is straightforward: a cancer-killing drug is chemically linked to an antibody that targets the delivery of the therapy to a tumor. This drug class ...
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology ...
Explore the role of patient-derived biology in enhancing antibody-drug conjugates for more effective cancer treatment.
PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced its plans to ...
First scalable single-use mixer specifically designed for ADC manufacturing Increases efficiency by 70% compared to stainless steel or glass manufacturing methods Utilizes Ultimus ® Film for superior ...
Presentations to highlight preclinical data supporting the clear differentiation of Adcentrx's clinical-stage ADRX-0405 STEAP1 ADC and preclinical ADRX-0134 NaPi2b ADC Adcentrx to present new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback